Synthesis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine against cytomegalovirus and orthopoxviruses

被引:53
作者
Beadle, JR
Wan, WB
Ciesla, SL
Keith, KA
Hartline, C
Kern, ER
Hostetler, KY [1 ]
机构
[1] Univ Calif San Diego, Dept Med, VA San Diego Healthcare Syst, La Jolla, CA 92093 USA
[2] Univ Alabama, Sch Med, Dept Pediat, Birmingham, AL 35233 USA
关键词
D O I
10.1021/jm050473m
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
9-(S)-(3-Hydroxy-2-phosphonomethoxypropyl)adenine [(S)-HPMPA] was one of the first acyclic nucleoside phosphonates described and has been reported to have good antiviral activity against most double-stranded DNA viruses, including the herpes group viruses and the orthopoxviruses. However, (S)-HPMPA is not orally bioavailable and has not been developed for clinical use. We have prepared orally bioavailable lipid esters of (S)-HPMPA and report their synthesis and antiviral evaluation against cytomegalovirus and orthopoxviruses. These esters were evaluated in vitro in cells infected with human cytomegalovirus (HCMV), murine cytomegalovirus (MCMV), vaccinia (VV), and cowpox viruses (CV). The most active compound, oleyloxyethyl-(S)-HPMPA, was found to have EC50 value of 0.003 mu M against HCMV vs 1.4 mu M for unmodified HPMPA. In cells infected with VV and CV, octadecyloxyethyl-(S)-HPMPA had EC50 values of 0.01-0.02 mu M versus 2.7 -4.0 mu M for unmodified HPMPA. When compared with the alkoxyalkyl esters of cidofovir, the corresponding alkoxyalkyl esters of (S)-HPMPA were equally active against HCMV and MCMV but were 15-20-fold more active against VV and CV in vitro. The alkoxyalkyl esters of (S)-HPMPA are promising new compounds worthy of further investigation for treatment of infections caused by herpes viruses and orthopoxviruses.
引用
收藏
页码:2010 / 2015
页数:6
相关论文
共 37 条
[21]   Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication [J].
Keith, KA ;
Hitchcock, MJM ;
Lee, WA ;
Holy, A ;
Kern, ER .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (07) :2193-2198
[22]   In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication [J].
Kern, ER ;
Kushner, NL ;
Hartline, CB ;
Williams-Aziz, SL ;
Harden, EA ;
Zhou, SM ;
Zemlicka, J ;
Prichard, MN .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (03) :1039-1045
[23]   In vitro activity of potential anti-poxvirus agents [J].
Kern, ER .
ANTIVIRAL RESEARCH, 2003, 57 (1-2) :35-40
[24]   Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir [J].
Kern, ER ;
Hartline, C ;
Harden, E ;
Keith, K ;
Rodriguez, N ;
Beadle, JR ;
Hostetler, KY .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (04) :991-995
[25]   Alkoxy propane prodrugs of foscarnet: effect of alkyl chain length on in vitro antiviral activity in cells infected with HIV-1, HSV-1 and HCMV [J].
Kini, GD ;
Beadle, JR ;
Xie, H ;
Aldern, KA ;
Richman, DD ;
Hostetler, KY .
ANTIVIRAL RESEARCH, 1997, 36 (01) :43-53
[26]   Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate [J].
Magee, WC ;
Hostetler, KY ;
Evans, DH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (08) :3153-3162
[27]   Design and development of oral drugs for the prophylaxis and treatment of smallpox infection [J].
Painter, GR ;
Hostetler, KY .
TRENDS IN BIOTECHNOLOGY, 2004, 22 (08) :423-427
[28]  
Prichard Mark N., 2005, Current Drug Targets - Infectious Disorders, V5, P17, DOI 10.2174/1568005053174627
[29]   Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir [J].
Quenelle, DC ;
Collins, DJ ;
Wan, WB ;
Beadle, JR ;
Hostetler, KY ;
Kern, ER .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (02) :404-412
[30]   Effective metabolism and long intracellular half life of the anti-Hepatitis B agent adefovir in hepatic cells [J].
Ray, AS ;
Vela, JE ;
Olson, L ;
Fridland, A .
BIOCHEMICAL PHARMACOLOGY, 2004, 68 (09) :1825-1831